thymosin alpha 1-interferon alpha-2b fusion protein (Zhejiang Chinagene Biopharmaceutical/Shanghai Institute of Biochemistry and Cell Biology)

N/A

Report date: 2025/01/26 17:14:11

Base Information

Drug Namethymosin alpha 1-interferon alpha-2b fusion protein (Zhejiang Chinagene Biopharmaceutical/Shanghai Institute of Biochemistry and Cell Biology)
Drug Alias NameSIBS01-009
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterferon alpha 2 ligandThymosin receptor agonistsThymosin alpha-1 ligand
TargetsThymosin receptorInterferon alpha-2Thymosin alpha-1
Therapy Area/IndicationsNeoplasmsVirus Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Institute of Biochemistry and Cell Biology
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Zhongqi Biological Pharmaceutical Co LtdShanghai Institute of Biochemistry and Cell Biology
Inactive CompaniesN/A
Active IndicationsNeoplasmsVirus Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A